EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors

Key Inclusion Criteria: * Recurrent or metastatic solid tumors that have been histologically or cytologically pathologically confirmed and are not amenable to radical treatment with surgery or local therapy. * Patients with advanced or recurrent solid tumors who have failed prior standard therapy. * Expected survival period \>6 weeks at the time of informed consent. * Adequate organ function * Eastern Cooperative Oncology Group (ECOG) Physical Status Score 0 to 1. * Is willing to provide archival or fresh tumor tissue samples for EVM16 production. * Has adequate treatment washout period prior to first study dose. * Has at least one measurable lesion as assessed by the investigator according to RECIST version 1.1 criteria before enrollment. Key Exclusion Criteria: * Primary central nervous system (CNS) malignancies that are symptomatic, untreated, or in need of curative treatment, or subjects with CNS metastases. * Uncontrolled co-morbidities. * Cerebrovascular event (stroke, transient ischemic attack, etc.) within 4 months prior to the signing of inform consent form. * In screening period male QTcF interval \>450 ms; Female QTcF interval \>470 ms (calculated by the Fridericia formula). * Left ventricular ejection fraction (LVEF) \< 50% during the screening period. * Diagnosis of immunodeficiency, or history or syndrome of active as well as former autoimmune disease with risk of relapse, or a disease requiring systemic steroid hormone or immunosuppressive drug therapy. * Subjects with a history of positive human immunodeficiency virus (HIV) test or acquired immunodeficiency syndrome (AIDS). * Co-infection HBV and HCV. * Presence of any active infection requiring systemic therapy. * Patients who are still on any other investigational medications treatment at the time of screening. * Previous treatment with cell therapy, tumor vaccines, cytokines, or growth factors for cancer control. * Patients with prior intolerance to tislelizumab resulting in permanent termination of tislelizumab. * History or presence of significant lung disease.